Clinical Trials Arena June 14, 2024
The mRNA-1283 vaccine demonstrated higher efficacy in adults aged 18 years and above.
Moderna has announced that its Phase III clinical trial of the investigational next-generation Covid-19 vaccine, mRNA-1283, met its primary efficacy endpoint.
The vaccine demonstrated non-inferior efficacy against Covid-19 compared to Spikevax (mRNA-1273).
Notably, the trial observed higher efficacy in adults aged 18 years and above, with a consistent trend reported in those aged 65 years and older.
The observer-blind, randomised, active-controlled study involved approximately 11,400 participants aged 12 and above.
Participants were administered either a 10μg dose of mRNA-1283 or a 50μg dose of Spikevax.
In March this year, the company reported positive interim immunogenicity data from the vaccine trial.
The latest efficacy data align with the...
Today's Sponsors
Today's Sponsor